VCNX - Vaccinex, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Vaccinex, Inc.

1895 Mount Hope Avenue
Rochester, NY 14620
United States

Full Time Employees44

Key Executives

NameTitlePayExercisedYear Born
Dr. Maurice ZaudererCo-Founder, CEO, Pres & Director336.77kN/A1945
Mr. Raymond E. WatkinsSr. VP & COO235.37kN/A1958
Dr. Ernest S. SmithSr. VP of Research & Chief Scientific Officer235.48kN/A1972
Dr. Deepak M. SahasrabudheCo-Founder, Sr. Mang. of Laboratory Operations & Safety and Scientific & Clinical AdvisorN/AN/AN/A
Mr. Scott E. Royer C.F.A., M.B.A.Chief Financial OfficerN/AN/A1974
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), osteosarcoma, melanoma, and Huntington's disease. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and potentially for other autoimmune disorders; VX25, a bi-specific natural killer T (NKT) cell stimulator, for the therapeutic application of NKT cell stimulation for cancer immunotherapy; BVX20, an investigational and humanized monoclonal antibody for the treatment of for multiple sclerosis. It has a clinical trial collaboration and supply agreement with Merck KGaA to test pepinemab in combination with avelumab checkpoint inhibitor in NSCLC patients. Vaccinex, Inc. was founded in 2001 and is headquartered in Rochester, New York.

Corporate Governance

Vaccinex, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.